Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis.

Q3 Medicine Gastroenterology and Hepatology From Bed to Bench Pub Date : 2023-01-01 DOI:10.22037/ghfbb.v16i1.2685

Teodoro J Oscanoa, Xavier Vidal, Julio Luque, Dante I Julca, Roman Romero-Ortuno

{"title":"Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis.","authors":"Teodoro J Oscanoa, Xavier Vidal, Julio Luque, Dante I Julca, Roman Romero-Ortuno","doi":"10.22037/ghfbb.v16i1.2685","DOIUrl":null,"url":null,"abstract":"Aim: The aim of the present study was to conduct a meta-analysis of the frequency of isoniazid-induced liver injury (INH-ILI) in patients receiving isoniazid (INH) preventative therapy (IPT).Background: The frequency of hepatotoxicity (drug-induced liver injury: DILI) of antituberculosis drugs has been studied, especially when INH, rifampin, and pyrazinamide are co-administered. However, little is known about the frequency of DILI in patients with latent tuberculosis infection (LTBI), where IPT is indicated.Methods: We searched PubMed, Google Scholar, and the Cochrane Database of Systematic Reviews for studies reporting the frequency of INH-ILI in patients with IPT using one or more diagnostic indicators included in the criteria of the DILI Expert Working Group.Results: Thirty-five studies comprising a total of 22,193 participants were included. The overall average frequency of INH-ILI was 2.6% (95% CI, 1.7-3.7%). The mortality associated with INH-DILI was 0.02% (4/22193). Subgroup analysis revealed no significant differences in the frequency of INH-ILI in patients older or younger than 50 years, children, patients with HIV, candidates for liver, kidney, or lung transplant, or according to the type of study design.Conclusion: The frequency of INH-ILI in patients receiving IPT is low. Studies on INH-ILI are needed where the current DILI criteria are used.","PeriodicalId":12636,"journal":{"name":"Gastroenterology and Hepatology From Bed to Bench","volume":"16 1","pages":"448-457"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/13/55/GHFBB-16-448.PMC10105504.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology and Hepatology From Bed to Bench","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22037/ghfbb.v16i1.2685","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The aim of the present study was to conduct a meta-analysis of the frequency of isoniazid-induced liver injury (INH-ILI) in patients receiving isoniazid (INH) preventative therapy (IPT).

Background: The frequency of hepatotoxicity (drug-induced liver injury: DILI) of antituberculosis drugs has been studied, especially when INH, rifampin, and pyrazinamide are co-administered. However, little is known about the frequency of DILI in patients with latent tuberculosis infection (LTBI), where IPT is indicated.

Methods: We searched PubMed, Google Scholar, and the Cochrane Database of Systematic Reviews for studies reporting the frequency of INH-ILI in patients with IPT using one or more diagnostic indicators included in the criteria of the DILI Expert Working Group.

Results: Thirty-five studies comprising a total of 22,193 participants were included. The overall average frequency of INH-ILI was 2.6% (95% CI, 1.7-3.7%). The mortality associated with INH-DILI was 0.02% (4/22193). Subgroup analysis revealed no significant differences in the frequency of INH-ILI in patients older or younger than 50 years, children, patients with HIV, candidates for liver, kidney, or lung transplant, or according to the type of study design.

Conclusion: The frequency of INH-ILI in patients receiving IPT is low. Studies on INH-ILI are needed where the current DILI criteria are used.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

异烟肼对潜伏肺结核感染者的肝毒性：一项荟萃分析。

目的：本研究旨在对接受异烟肼（INH）预防性疗法（IPT）的患者发生异烟肼诱发肝损伤（INH-ILI）的频率进行荟萃分析：背景：人们对抗结核药物的肝毒性（药物性肝损伤：DILI）发生率进行了研究，尤其是在 INH、利福平和吡嗪酰胺联合用药时。然而，对于适用于 IPT 的潜伏肺结核感染（LTBI）患者发生 DILI 的频率却知之甚少：方法：我们在 PubMed、谷歌学术和 Cochrane 系统综述数据库中搜索了使用 DILI 专家工作组标准中包含的一个或多个诊断指标报告 IPT 患者 INH-ILI 发生频率的研究：结果：共纳入 35 项研究，总计 22,193 名参与者。INH-ILI的总平均发生率为2.6%（95% CI，1.7-3.7%）。与 INH-DILI 相关的死亡率为 0.02%（4/22193）。亚组分析显示，在年龄大于或小于 50 岁的患者、儿童、HIV 感染者、肝、肾或肺移植候选者中，INH-ILI 的发生率无明显差异，研究设计类型也无明显差异：结论：接受 IPT 治疗的患者发生 INH-ILI 的频率较低。结论：在接受 IPT 的患者中，INH-ILI 的发生率较低，需要对使用现行 DILI 标准的 INH-ILI 进行研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Gastroenterology and Hepatology From Bed to Bench Medicine-Gastroenterology

CiteScore

2.30

自引率

0.00%

发文量